Parallel reductions of IgE and exhaled nitric oxide after optimized anti‐inflammatory asthma treatment

• DOI: 10.1002/iid3.103
• Publication Date: 2016-03-21T09:03:01Z
• Authors: Jörgen Syk; Andrei Malinovschi; Magnus P. Borres; Anna‐Lena Undén; Anna Andreasson; Mats Lekander; Kjell Alving
• Keywords: corticosteroid; Medicin och hälsovetenskap; leukotriene-receptor antagonist; breath test; atopy; Immunoglobulin E; Nitric Oxide; Medical and Health Sciences; Asthma; asthma control; immunoglobulin E; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; quality of life; Breath Tests; Exhalation; Quality of Life; Humans; Anti-Asthmatic Agents; FENO; Original Research; Follow-Up Studies

Abstract Immunoglobulin E (IgE) is crucial for the development of airway inflammation in atopic asthma, and inhibition IgE using monoclonal antibodies now part asthma therapy. However, impact ordinary anti‐inflammatory treatment on unclear. The aim this study was to investigate if optimization with inhaled corticosteroid (ICS) leukotriene‐receptor antagonist (LTRA) according symptoms or exhaled nitric oxide (F NO) levels over a one‐year period affects concentrations. Altogether, 158 relatively well‐controlled but multi‐sensitized asthmatics (age 18–65 years), ongoing ICS at baseline, were included post hoc analysis data from randomized, controlled trial F NO‐guided Asthma control quality life (Juniper ACQ mAQLQ), NO, serum measured baseline after one year. Concentrations six common perennial aeroallergens summed up (perennial IgE). We found that total decreased by 10.2% 16.0% ( P < .001 both comparisons). This not related allergen exposure, whereas use LTRA during year correlated reduction = .030 .013). decrease significantly NO .003 .001), improvements mAQLQ scores 0.05, all conclude patients persistent resulted significant decreases antibodies; these life. Thus, reduced controller medications effect seems be clinically important.